Document Type
Article
Publication Date
4-24-2018
Abstract
The mainstay of treatment for unresectable hepatocellular carcinoma is locoregional therapy including percutaneous ablation and transarterial chemo- and radioembolization. While monitoring for tumor response after transarterial chemoembolization is crucial, current imaging strategies are suboptimal. The standard of care is contrast-enhanced magnetic resonance imaging or computed tomography imaging performed at least 4 to 6 weeks after therapy. We present a case in which contrast-enhanced ultrasound identified a specific extra-hepatic collateral from the gastroduodenal artery supplying residual viable tumor and assisting with directed transarterial management.
Recommended Citation
Gummadi, Sriharsha; Stanczak, Maria; Lyshchik, Andrej; Forsberg, Flemming; Shaw, Colette M.; and Eisenbrey, John R., "Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization." (2018). Department of Radiology Faculty Papers. Paper 58.
https://jdc.jefferson.edu/radiologyfp/58
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
29721125
Language
English
Comments
This article has been peer reviewed. It is the author’s final published version in Radiology Case Reports, Volume 13, Issue 3, April 2018, Pages 713-718.
The published version is available at https://doi.org/10.1016/j.radcr.2018.04.001 . Copyright © Gummadi et al.